Healthcare Debt Financing: Bank, SBA, Private Credit and Asset-Based Options
Healthcare companies borrow from five lender types: banks, SBA-guaranteed lenders, asset-based lenders, private credit funds and family offices. Sellers supply a sixth layer through notes and earnouts. Banks are the cheapest and strictest. Private credit funds most PE roll-ups at a higher price. Asset-based lenders advance against receivables. Family offices that lend directly fill some of the gaps banks leave, on terms they set deal by deal.
The right source depends on EBITDA size, collateral, ownership and deadline.
Each market figure names its source, population and period. Worked examples are our arithmetic on stated hypothetical inputs.
Healthcare Debt Sources Compared: 6 Options by Cost, Collateral and Speed
| Source | Best fit | Relative cost | Collateral and guarantees | Covenants | Speed |
|---|---|---|---|---|---|
| Bank term loan and revolver | Profitable practices and groups with clean books and hard assets | Lowest | Blanket lien, real estate, personal guarantees on smaller deals | Tight: leverage, fixed charge coverage, minimum liquidity | Slow, with late diligence requests |
| SBA-guaranteed loan | Small practice acquisitions, partner buyouts, owner-occupied real estate | Low rate plus guarantee fees | Personal guarantees from significant owners, all available collateral | Moderate, heavy paperwork | Slow |
| Asset-based line (A/R) | Home health, labs, DME, staffing, fast growth with lumpy collections | Low to mid | First lien on receivables, cash sweep | Borrowing base, field exams | Fast once set up |
| Private credit and unitranche | PE-backed platforms buying add-ons | Mid to high | All assets, pledge of equity | Leverage tests on adjusted EBITDA | Fast, sponsor-driven |
| Family office direct loan | Deals a bank declined or cannot close in time, where the family office has healthcare appetite | High, sometimes with warrants | Negotiated: A/R, real estate, share pledge, guarantees | Bespoke | Depends on the principal |
| Seller note or earnout | Practice sales where the buyer's senior debt falls short | Set in the purchase agreement | Usually unsecured and subordinated | Standstill under an intercreditor | Closes with the deal |
Decision checklist:
- Owner-operated practice buying a building, equipment or a partner's shares: start with a bank, then an SBA lender.
- Receivables-heavy business with long payer lag: price an asset-based line before a cash-flow term loan.
- PE-backed platform acquiring practices: private credit with a delayed draw facility is the default.
- Bank said no, or said yes too slowly: approach family office lenders with a healthcare track record, and pair the loan with a seller note.
- Owner taking cash out without selling control: compare a dividend recap against a minority sale. See healthcare recapitalization.
Senior secured debt sits at the bottom of the stack. It costs the least and gets repaid first. Each layer above it costs more because it recovers less in a default. The healthcare capital stack infographic maps each layer to the investors who hold it.
Which Lender Fits Your Subsector
Business model decides the first call more than size does. Cash-flow lenders want stable EBITDA. Asset-based lenders want collectible receivables. A pre-profit company has neither, so it goes to a different lender group entirely.
| Business | First lender to approach | Why | What slows approval |
|---|---|---|---|
| Physician, dental or optometry practice, owner-operated | Bank, then SBA lender | Stable cash flow, hard assets, personal guarantees available | Key-provider dependence, thin financials |
| Practice joining a PE platform | The platform's private credit lender, through its delayed draw | Your price is funded from the platform's facility | Add-back caps, remaining draw capacity |
| ASC | Bank or private credit for the business, separate real estate loan | High margins support leverage, real estate finances separately | Surgeon concentration, payer rate resets |
| Home health, hospice, labs, DME | Asset-based lender | Receivables are the main asset | Government payer share, denial rates |
| Behavioral health | Private credit or a family office with sector experience | Banks are cautious on reimbursement and licensing risk | License transfer timing, census volatility |
| Healthtech with recurring revenue, pre-profit | Venture debt and recurring-revenue lenders | They size against recurring revenue and the equity sponsors behind the company, not EBITDA | Burn rate, cash runway, customer concentration |
| Healthcare services (billing, staffing, MSO) | Bank or ABL, depending on margin | Contracted receivables, light assets | Client concentration, contract terms |
10 Terms to Compare in Every Lender Quote
Spreads, advance rates and leverage levels move with the base rate and lender appetite. A published range goes stale before a deal closes. The benchmark that holds up is three live term sheets built on the same assumptions.
How to run the quote process:
- Send every lender the same package: QoE bridge, A/R aging by payer, provider roster, and the same EBITDA definition.
- Ask for an indicative term sheet covering spread, floor, fees, amortization, covenants and guarantees.
- Convert each quote into year-one debt service, year-one financing cost and an all-in yield over your expected hold.
- Run each quote through your downside case before you negotiate rate.
| Term | What to ask | Healthcare angle |
|---|---|---|
| Interest rate | Fixed, or a spread over SOFR? Is there a floor? | A floating rate and a reimbursement cut can hit coverage in the same year |
| Upfront and unused fees | Closing fee or original issue discount, unused line fee, delayed draw ticking fee | Fees on undrawn add-on capacity accrue while the pipeline stalls |
| Maximum senior and total leverage | Multiple of which EBITDA definition? | QoE adjustments and add-back caps change the loan more than the multiple does |
| Fixed charge coverage minimum | What counts as a fixed charge? Is rent included? | Sale-leasebacks and new clinic leases push rent into the test |
| Amortization and interest-only period | Annual principal due, and any interest-only months | Interest-only time covers a new surgeon or site ramp |
| EBITDA add-back cap | How much synergy and pro forma credit is allowed? | Sets how much a platform can pay for an add-on |
| Personal guarantees | Who signs, for how much, and when does it fall away? | Physician owners carry this risk after the sale |
| Prepayment terms | Penalty schedule and refinancing rights | A planned recap or sale inside two years makes this expensive |
| Change of control | Is the loan portable to a new owner? | A sponsor-to-sponsor sale usually forces a refinancing |
| Commitment expiry | How long does the commitment stay open, and at what cost? | Regulatory reviews can outlast a standard commitment |
Worked example 1: comparing two $10.0M quotes. Our arithmetic. All terms are hypothetical. Assumes interest on the opening balance, no change in the base rate, and fees paid at closing.
| Year one | Quote A: bank | Quote B: private credit |
|---|---|---|
| Rate | 7.75% | 10.50% |
| Upfront fee | 0.75% = $0.075M | 2.00% = $0.200M |
| Annual amortization | 10% = $1.000M | 1% = $0.100M |
| Interest | $10.0M × 7.75% = $0.775M | $10.0M × 10.50% = $1.050M |
| Debt service (interest plus principal) | $1.775M | $1.150M |
| Financing cost (interest plus fee) | $0.850M | $1.250M |
| Approximate all-in yield, 3-year hold | 7.75% + 0.75% ÷ 3 = 8.00% | 10.50% + 2.00% ÷ 3 = 11.17% |
| Prepayment premium | None | 2% in year one, 1% in year two |
| Personal guarantee | Yes | No |
The all-in yield spreads the upfront fee evenly over three years and ignores time value and amortization. It is a ranking tool, not a precise yield.
Quote B costs $0.40M more in year one but needs $0.625M less cash for debt service. If the owner refinances B early in year two, the premium is 1% × $9.9M balance = $0.099M. The cheaper loan is the better loan only if the business can carry the faster amortization and the owners accept the guarantee.
What Each Lender Underwrites in a Healthcare Borrower
The same practice looks different to each lender. Prepare the file for the lender you are approaching.
| Lender | Primary test | Healthcare items that move the answer |
|---|---|---|
| Bank | Historical cash flow and hard collateral | Payer concentration, provider retention, compliance history |
| SBA lender | Owner cash flow and personal credit | Buyer's clinical credentials, seller transition period, treatment of the seller note |
| ABL lender | Speed and reliability of collections | Days in A/R by payer, denial rate, government versus commercial split |
| Private credit | Pro forma adjusted EBITDA of the platform | Add-on pipeline, synergy support, sponsor track record |
| Family office | Downside recovery and the principal's view of the business | Real estate value, license and certificate of need (CON) status, owner commitment |
Before the first lender meeting:
- [ ] Quality of earnings (QoE) report, or at least a QoE-style EBITDA bridge
- [ ] A/R aging by payer, with 12 months of denials and write-offs
- [ ] 13-week cash flow forecast
- [ ] Covenant model with a downside case: loss of a top provider, a commercial rate cut and a base rate rise
- [ ] Provider list with contract terms, restrictive covenants and credentialing status
- [ ] Signed term sheet in hand before LOI exclusivity starts
- [ ] Commitment expiry mapped against every regulatory step on the deal
Bank Term Loans and Revolvers: The 8 Items a Credit Committee Checks
A bank lends against reported cash flow and hard collateral. The credit officer will ask for:
- Multi-year tax returns plus reviewed or audited financial statements
- Payer mix, with concentration in any single commercial payer flagged
- A/R aging by payer, with denial and write-off rates
- Personal guarantees from physician or founder owners on smaller loans
- Real estate and equipment appraisals
- Licenses, Medicare enrollment and credentialing status for every provider
- Employment agreements and restrictive covenants for the producing providers
- Compliance history: payer audits, recoupments, self-disclosures and open investigations
Bank money is cheap and carries execution risk. A request for new diligence after the purchase agreement is signed can push the closing past the outside date or cut the loan amount.
A buyer or recapitalizing owner can protect the deal in three ways. Get a signed bank term sheet before the LOI exclusivity clock starts. Negotiate a seller note large enough to close if the bank cuts the loan. Refinance into cheaper bank debt after closing, on your own timeline.
SBA-Guaranteed Loans for Small Practice Buyouts and Real Estate
SBA eligibility turns on the SBA's size standards and program loan limits, not physician headcount. Both are published on SBA.gov's 7(a) loan page (U.S. Small Business Administration, accessed November 2026) and change by rule, so confirm the current figures with the lender. The 7(a) program covers acquisitions, partner buyouts and working capital. The 504 program finances owner-occupied real estate and major equipment.
The market for SBA lending in medicine is the small private practice. The AMA Policy Research Perspective Physician Practice Characteristics in 2024, published in 2025 from the AMA's 2024 Physician Practice Benchmark Survey, found that 42.2 percent of physicians were in private practice in 2024, down from 60.1 percent in 2012. Of those private-practice physicians, 49.2 percent worked in practices with fewer than five physicians.
Private ownership also varies by specialty, so check the AMA's specialty detail for your own field before planning a buyout.
Specialties with high private ownership have more partner buyouts and internal successions to finance. Those are the core SBA use cases.
Where SBA loans fit:
- A younger physician buying out a retiring partner's shares
- An associate dentist or optometrist buying the practice they work in
- Owner-occupied real estate and major imaging or surgical equipment, through 504
- Working capital for a de novo location of an existing practice
The trade-offs:
- The government guarantee lets the bank accept less collateral and offer a longer term than a conventional loan.
- The buyer still contributes equity, and SBA rules govern how much of it can come from a seller note.
- Significant owners sign personal guarantees, and the lender takes all available business collateral.
- Guarantee fees and documentation add cost and time.
- Program loan limits make SBA a small-practice tool. It will not fund a platform or a PE add-on program.
Five questions to put to every SBA lender before the LOI:
| Question | Effect on the deal |
|---|---|
| What is the current maximum loan for this structure? | Sets whether SBA alone can fund the price |
| What minimum equity injection do you require? | Sets the buyer's cash at close |
| Can a seller note count toward that equity? | Changes how much cash the buyer needs |
| If it counts, must the note sit on standby, and for how long? | A note on standby pays the seller nothing during that period |
| Does the seller need a transition or employment period? | Ties the seller to the practice after closing |
Put the standby answer in front of the seller early. It changes their cash at close and their cash in the first years after.
Asset-Based Lending on Healthcare Receivables: Borrowing Base Math
An asset-based lender advances against eligible receivables. The lender cares less about EBITDA than about how quickly and reliably claims turn into cash. That makes ABL a natural fit for home health, labs, DME suppliers, staffing firms and fast-growing practices whose collections lag revenue.
Worked example 2: borrowing base before concentration limits. Our arithmetic. All inputs are hypothetical, including the 85% advance rate.
| Line | Amount |
|---|---|
| Gross A/R | $6.0M |
| Less claims over the lender's aging cutoff | ($0.7M) |
| Less denied, disputed and self-pay balances | ($0.5M) |
| Eligible A/R | $4.8M |
| Advance rate (assumed) | 85% |
| Availability | $4.08M |
Worked example 3: same borrower with a payer concentration cap. Our arithmetic. Assumes one commercial payer holds $1.8M of the $4.8M eligible pool (37.5%) and the lender caps any single payer at 25% of eligible A/R.
- Cap: 25% × $4.8M = $1.2M
- Excess over cap: $1.8M less $1.2M = $0.6M, removed from the base
- Revised eligible A/R: $4.8M less $0.6M = $4.2M
- Availability: $4.2M × 85% = $3.57M
One payer contract cost the borrower $0.51M of availability. Diversifying the commercial book raises the line more than any rate negotiation will.
How government receivables are handled. Medicare and Medicaid pay the provider, not the lender. Lenders typically take a security interest in the receivables and in the cash once it lands in the provider's account, and the standard structure is built around that payment flow:
| Payer type | Where payments land | Lender control | Underwriting effect |
|---|---|---|---|
| Medicare and Medicaid | Deposit account in the provider's name | Lien on the account plus a standing sweep to a lender account, on a schedule set in the loan documents | Often lower advance rates or larger reserves on the government book, depending on the lender |
| Commercial payers | Account subject to a deposit account control agreement | Lender can take control of the account on a default | Standard advance rates, subject to concentration caps |
Lenders also run field exams that test billed claims against collected cash. A rising denial rate shows up in the borrowing base within weeks, so fix revenue cycle problems before opening the line.
The security package. In a healthcare credit, each collateral item takes a specific form:
| Security item | Healthcare form | Have ready |
|---|---|---|
| Receivables | A/R split by Medicare, Medicaid, commercial and self-pay | Aging by payer, 12 months of denials and write-offs |
| Cash control | Provider-owned government account with a sweep, lender-controlled commercial account | Signed deposit account control agreements and sweep instructions |
| Real estate | Owned clinic, ASC or office building | Title, appraisal, environmental report |
| Insurance | Property, malpractice and key-person coverage | Certificates naming the lender as loss payee or additional insured |
| Licenses | Facility licenses, CON status, Medicare enrollment | Current copies and change-of-ownership history |
The same file works for an ABL lender, a bank or a family office.
Private Credit in PE Roll-Ups: Delayed Draws, Add-Backs and Your Price
Private credit finances most sponsor-led healthcare consolidation. The Private Equity Stakeholder Project's 2025 review tracked 1,029 PE-backed U.S. healthcare deals in calendar 2025, using PitchBook and LevinPro HC data. PESP states that its count is likely an underestimate.
| PE-backed healthcare deals tracked by PESP, calendar 2025 | Count |
|---|---|
| Leveraged buyouts | 151 |
| Add-on acquisitions | 664 |
| Growth investments | 214 |
| Total deals | 1,029 |
| Platform companies involved | 420 |
| Investment firms involved | 708 |
The busiest subsectors in the PESP data were health IT (151 deals), dental care (149), outpatient care (148), medtech (117) and behavioral health (56). PESP found 95% of the dental deals were add-ons by PE-owned platforms. Add-ons outnumbered buyouts more than four to one in that dataset (our arithmetic: 664 ÷ 151 = 4.4).
PESP counts deals, not funding sources. A platform pays for an add-on with some mix of delayed draw borrowings, sponsor equity, seller rollover and earnouts. The platform's credit agreement sets the debt share.
Bain & Company's Global Healthcare Private Equity Report 2026 press release measures a different population: global healthcare PE buyouts, by value. Do not compare its counts with PESP's U.S. counts.
| Global healthcare PE, calendar 2025 (Bain estimates, published 2026) | Figure |
|---|---|
| Deal value | Estimated $191 billion, a record above the 2021 peak |
| Buyouts announced | 445, second-most on record |
| Sponsor-to-sponsor deal value | More than $120 billion |
| Exit value | Expected $156 billion, up from $54 billion the prior year |
| North American deals above $1 billion | 26 as of November 2025, against 14 in the full prior year |
| Share of those large deals that were sponsor-to-sponsor | More than 70% |
Credit agreements commonly treat a change of control as an event of default, though terms vary by lender. A sponsor-to-sponsor sale therefore often refinances the platform's debt and resets the leverage tests that govern its next round of add-ons.
On the physician side, the AMA's 2024 Benchmark Survey reports that 6.5 percent of physicians worked in PE-owned practices that year, up from about 4.5 percent in both 2020 and 2022.
How the debt works inside a roll-up:
- Unitranche facility. One lender or club holds a single loan in place of separate senior and junior tranches. Execution is faster and the price is higher.
- Delayed draw term loan. Committed capital that the platform draws to pay for each add-on. Every draw is tested against a leverage ratio.
- Pro forma EBITDA add-backs. The lender credits the acquired practice's earnings and a capped amount of synergies. The size of that cap determines how much the platform can pay you.
- Equity cure rights. The sponsor can inject equity to cure a covenant breach.
Worked example 4: how the platform's leverage test sets your price. Our arithmetic. Assumes a hypothetical dental platform with $20.0M of adjusted EBITDA, $95.0M of debt (4.75x) and a 5.25x total leverage test on each draw. It wants to buy your practice, which has $2.0M of QoE-adjusted EBITDA. Fees are ignored.
- Pro forma EBITDA: $20.0M + $2.0M = $22.0M
- Maximum debt after the draw: 5.25 × $22.0M = $115.5M
- Draw capacity: $115.5M less $95.0M = $20.5M
- If the lender credits only $1.5M of your EBITDA: 5.25 × $21.5M = $112.875M, so capacity falls to $17.875M
| Purchase price | Price at multiple of your $2.0M | Fits if lender credits $2.0M? | Fits if lender credits $1.5M? |
|---|---|---|---|
| 8.0x | $16.0M | Yes | Yes |
| 10.0x | $20.0M | Yes | No, $2.125M short |
The table tests only whether the debt share could reach the price. In practice platforms rarely fund an add-on entirely with debt, and sponsor equity, rollover and earnouts usually cover part of the price even when draw capacity would allow more.
For a seller, the platform's credit agreement sets the ceiling on price and the mix of cash and rollover. FOCUS Investment Banking's Dermatology Practice Valuation: 2026 Benchmarks describes platform-ready dermatology practices, which it frames as typically $5M+ of EBITDA, as often receiving 70%+ cash at close with meaningful rollover. FOCUS counts more than 35 sponsor-backed dermatology platforms operating nationally. Smaller add-ons should expect less cash at close.
Three questions to ask the platform before you sign an LOI:
- Which leverage test governs the draw that funds my price?
- How much delayed draw capacity remains, and when does the commitment expire?
- How much of my EBITDA will the lender credit, and what add-backs does it reject?
Your rolled equity sits behind all of that debt. Read healthcare deal structures before signing.
Family Office Loans and Subordinated Notes: Pricing and Structure
Family offices vary more than any other lender group. Some lend directly on healthcare deals, many avoid regulated healthcare credit entirely, and others lend only against real estate or other hard collateral. The ones that lend price above bank debt and some ask for warrants. The borrower gets structure in return: interest-only periods, payments sized to reimbursement cycles, and a decision maker who reads the business directly.
A behavioral health operator waiting on a state license transfer fits this profile. So does an ASC partnership buying out a departing surgeon on a fixed date. See how family offices invest in healthcare for their structures.
Lender or investor: two different transactions.
| Family office direct loan | Subordinated notes sold to individuals | |
|---|---|---|
| Counterparty | One family office, negotiating principal to principal | Many physicians or other individual investors |
| Documentation | Credit agreement, security agreement, intercreditor | Offering documents, subscription agreements, note |
| Position | Senior or second lien, secured as negotiated | Usually unsecured and junior to all bank debt |
| Regulatory character | Private loan | Raises securities offering questions for your attorney |
Terms to settle with a family office lender:
- Interest-only period and when amortization starts
- Cash versus paid-in-kind interest
- Warrant coverage, if any, and how it dilutes owners at exit
- Intercreditor position against any bank lender
- Board observer or reporting rights
- Refinancing rights once a bank will take out the loan
Notes sold to a group of physician investors raise securities and referral questions that a single lender does not. The mechanics are covered in raising capital from physician investors. Take the specific questions there to your own attorney.
Worked Example 5: Financing a $32.0M ASC Acquisition With 3 Layers
Hypothetical inputs: an ASC with $4.0M of QoE-adjusted EBITDA sells at 8.0x for $32.0M, measured as enterprise value before fees. The senior lender caps debt at 3.0x EBITDA and requires 1.25x fixed charge coverage. Senior debt costs 8.5% floating with 5% annual amortization. The seller carries a 6.0% interest-only note equal to 1.0x EBITDA. Maintenance capex is $0.4M and cash taxes are $0.5M. The ASC pays no rent because it owns its building.
Fixed charge coverage definition used here (an illustrative convention, since each lender defines the test and the treatment of leaseback rent in its own credit agreement): (EBITDA less maintenance capex less cash taxes) ÷ (cash interest plus scheduled principal). When the borrower pays rent, the numerator uses EBITDAR (EBITDA before rent) and rent joins the denominator.
| Sources | Amount | Multiple of EBITDA |
|---|---|---|
| Senior term loan | $12.0M | 3.0x |
| Seller note | $4.0M | 1.0x |
| Buyer equity | $16.0M | 4.0x |
| Total | $32.0M | 8.0x |
Debt service:
- Senior interest: $12.0M × 8.5% = $1.02M
- Senior amortization: $12.0M × 5% = $0.60M
- Seller note interest: $4.0M × 6.0% = $0.24M
- Total debt service: $1.86M
Fixed charge coverage:
- EBITDA $4.0M, less capex $0.4M, less cash taxes $0.5M = $3.1M
- $3.1M ÷ $1.86M = 1.67x
Which test binds? At 1.25x, $3.1M of cash flow supports $2.48M of debt service ($3.1M ÷ 1.25). Less the $0.24M seller note interest, $2.24M is left for senior debt. Each senior dollar costs 13.5% a year (8.5% interest plus 5% amortization), so coverage alone would allow $2.24M ÷ 13.5% = $16.6M, or 4.15x. The 3.0x leverage cap allows $12.0M. Leverage binds in this deal. In a lower-margin, capex-heavy or rent-heavy business, the order flips.
Cushion against the 1.25x covenant:
- Required cash flow: 1.25 × $1.86M = $2.325M
- Add back capex and taxes: $2.325M + $0.9M = $3.225M of EBITDA
- EBITDA can fall $0.775M, or 19.4%, before the covenant trips
Same deal with interest-only senior debt in year one:
| Metric | Amortizing | Interest-only year one |
|---|---|---|
| Debt service | $1.86M | $1.26M |
| Fixed charge coverage | 1.67x | 2.46x |
| EBITDA needed for 1.25x | $3.225M | $2.475M |
| EBITDA cushion | 19.4% | 38.1% |
Total leverage is 4.0x and senior leverage is 3.0x in both cases. One year of interest-only nearly doubles the cushion while new surgeons ramp.
Downside test on the amortizing structure. Our arithmetic. Assumes losing a high-volume surgeon cuts EBITDA 15% ($0.6M) and SOFR rises 100 basis points on the senior loan. Cash taxes are held at $0.5M, which is conservative because lower EBITDA would reduce them.
| Scenario | Cash flow for coverage | Debt service | Coverage | Against 1.25x |
|---|---|---|---|---|
| Base case | $3.1M | $1.86M | 1.67x | Passes |
| Surgeon loss, EBITDA down 15% | $2.5M | $1.86M | 1.34x | Passes |
| Rate up 100 bp (senior interest $1.14M) | $3.1M | $1.98M | 1.57x | Passes |
| Both together | $2.5M | $1.98M | 1.26x | Passes by 0.01x |
The structure survives either shock alone and barely survives both. A commercial rate cut on top would trip the covenant. That is the case for an interest rate hedge, an interest-only period or a lower senior multiple.
Test your own figures with the debt capacity calculator. Lenders size against QoE-adjusted EBITDA, not the owner's figure, so start with the QoE prep checklist.
Seller Notes, Earnouts and Sale-Leasebacks: Debt That Comes From the Deal
Deferred consideration is financing provided by the seller. SRS Acquiom's 2026 M&A Earnout and Milestone Trends covers private-target deals in SRS Acquiom's own dataset across all industries, not healthcare alone. It found earnouts in 24% of 2025 deals excluding life sciences. Among U.S. private equity buyers in that dataset, earnout use was 24% in 2025, against 13% across 2014 to 2022. Each earnout dollar is a dollar the buyer did not borrow at closing.
Seller note terms to negotiate:
- Interest rate, and whether interest is paid in cash or accrues
- Maturity relative to the senior loan
- Standstill period under the intercreditor agreement
- Offset rights the buyer can use against indemnity claims
- Acceleration on a change of control or a senior default
Sale-leasebacks turn owned real estate into cash at closing and replace it with long-term rent. That rent hits the financing twice. It comes out of EBITDA, which shrinks the base the leverage cap applies to. It also counts as a fixed charge.
Worked example 6: Example 5 with a sale-leaseback. Our arithmetic. Assumes the buyer sells the ASC building at closing for $6.0M and leases it back at $0.5M a year (an 8.3% rent yield on the sale price). The $6.0M replaces buyer equity. EBITDA after rent is $3.5M and EBITDAR stays $4.0M. Cash taxes are held at $0.5M for comparability. Rent is deductible, so actual taxes would fall slightly and coverage would rise slightly.
| Metric | Base case (owns building) | Leaseback, senior unchanged | Leaseback, senior resized to 3.0x |
|---|---|---|---|
| EBITDA after rent | $4.0M | $3.5M | $3.5M |
| Senior loan | $12.0M | $12.0M | 3.0 × $3.5M = $10.5M |
| Senior leverage | 3.0x | 3.43x, above the cap | 3.0x |
| Seller note | $4.0M | $4.0M | $4.0M |
| Leaseback proceeds | None | $6.0M | $6.0M |
| Buyer equity | $16.0M | $10.0M | $11.5M |
| Debt service | $1.86M | $1.86M | $0.8925M + $0.525M + $0.24M = $1.66M |
| Fixed charges including rent | $1.86M | $2.36M | $2.16M |
| Coverage numerator (EBITDAR less capex and taxes) | $3.1M | $3.1M | $3.1M |
| Fixed charge coverage | 1.67x | 1.31x | 1.44x |
The middle column does not work. The senior loan breaches the 3.0x cap once rent comes out of EBITDA, and coverage sits a hair above 1.25x. Resizing the senior loan restores the cap and lifts coverage to 1.44x, but the cushion shrinks. EBITDAR can fall about $0.40M, or 10.1%, before the 1.25x covenant trips (our arithmetic: 1.25 × $2.1575M = $2.697M, plus $0.9M of capex and taxes = $3.597M, against $4.0M). That compares with 19.4% in the base case.
The leaseback still cut the buyer's equity check by $4.5M. Size the leaseback and the rent before the senior loan, and show the lender the resized structure on day one.
Regulatory Items That Move the Financing Calendar
Healthcare deals carry regulatory steps that a commitment letter has to outlast. Federal premerger notice and a growing set of state healthcare transaction laws can add weeks or months between signing and closing, and some states can review or approve a deal before it closes. Ask lenders for a commitment expiry and ticking fee schedule built around those steps, and line up a bridge or a larger seller note in case a review runs long.
Closing-Step Financing Planner for Healthcare Deals
Map each closing step to the financing protection that keeps the money in place if that step slips.
| Closing step | What can move the date | Financing protection to put in the term sheet |
|---|---|---|
| LOI signed, exclusivity starts | Lender diligence requests arriving late | Signed term sheet before exclusivity, with the diligence list attached |
| QoE and lender diligence | Disputes over add-backs, A/R aging and provider retention | Agreed EBITDA definition written into the term sheet |
| Purchase agreement signed | Regulatory filings and reviews begin | Commitment expiry later than the outside date, ticking fees fixed in advance |
| Federal and state transaction reviews | Review length the parties do not control | Commitment extension right, plus a bridge or larger seller note as backup |
| License transfers and certificate of need steps | State agency timing, especially in behavioral health and ASCs | Delayed funding or an interest-only period until the license moves |
| Medicare change of ownership and payer recredentialing | Gaps in collections after closing | Revolver or ABL capacity sized for slower cash, sweep accounts open before close |
| Funding | Missing account agreements or insurance certificates | Signed deposit account control agreements, sweep instructions and lender certificates in hand |
Worked example 7: a late senior loan cut on the Example 5 ASC. Our arithmetic, using Example 5 inputs. Assumes the lender cuts the senior loan from $12.0M to $10.5M a week before closing and the seller agrees to raise the 6.0% note from $4.0M to $5.5M to fill the gap. Buyer equity stays $16.0M.
| Metric | As committed | After the cut, larger seller note |
|---|---|---|
| Senior loan | $12.0M | $10.5M |
| Seller note | $4.0M | $5.5M |
| Senior debt service at 13.5% | $1.62M | $1.4175M |
| Seller note interest at 6.0% | $0.24M | $0.33M |
| Total debt service | $1.86M | $1.7475M |
| Fixed charge coverage on $3.1M | 1.67x | 1.77x |
The deal still closes at $32.0M and coverage improves, because seller paper is cheaper to service than amortizing senior debt. The cost lands on the seller, who carries $1.5M more of unsecured, subordinated risk. Agree the fallback note size with the seller at the LOI stage, when it is a contingency, rather than at closing, when it is a demand.
Federal premerger notice and state healthcare transaction reviews can set the length of this calendar. See the healthcare M&A process guide and take the questions there to your own attorney. Seller notes, earnouts and MSO collateral can also raise referral and ownership questions covered in healthcare compliance due diligence guide, which belong with the same attorney before the term sheet is signed.
Questions Owners Ask About Healthcare Debt
How much debt can a healthcare practice borrow?
Lenders size senior debt as a multiple of trailing EBITDA after quality of earnings adjustments. They then test the debt service on that loan against a fixed charge coverage minimum. The test that produces the smaller loan sets the amount. In a high-margin business with low capex, the leverage multiple usually binds. In a thin-margin, capex-heavy or rent-heavy business, coverage binds first. The ASC example on this page runs both tests on the same deal.
Is an SBA loan or a conventional bank loan better for buying a practice?
SBA-guaranteed loans generally allow a smaller equity injection and a longer term. That helps a younger physician buying out a retiring partner. They cost more in guarantee fees and paperwork, and the program caps loan size, so SBA suits partner buyouts and small acquisitions rather than platforms. A conventional bank loan suits an established group with strong collateral and owners who want fewer restrictions. Get quotes on both and compare payment size, equity required, guarantee terms and how each treats the seller note.
Why would a healthcare company borrow from a family office instead of a bank?
Some family offices lend directly on deals a bank declined or could not close in time. Typical cases are a concentrated payer mix, a pending state transaction review, a turnaround, or an acquisition with a fixed closing date. Appetite varies widely. Many family offices avoid regulated healthcare credit, and those that lend price above a bank and sometimes ask for warrants. A direct loan from one family office is negotiated principal to principal under a credit agreement. Selling subordinated notes to a group of individual investors is a different transaction that raises securities questions for your attorney.
Can Medicare and Medicaid receivables be used as loan collateral?
Lenders do finance them, with a different structure from commercial receivables. Medicare and Medicaid pay the provider, not the lender, so lenders typically take a security interest in the receivables and in the cash once it reaches the provider's account. Government payments land in a deposit account in the provider's name and sweep on a set schedule to a lender-controlled account. Lenders watch that sweep closely and apply lower advance rates or larger reserves to the government book. Commercial payer receivables sit under a standard deposit account control agreement.
Does a sale-leaseback reduce how much I can borrow?
Usually, yes. New rent comes out of EBITDA, so a lender sizing debt on a leverage multiple has less EBITDA to lend against. Rent also counts as a fixed charge, so coverage falls. In the hypothetical ASC on this page, a $6.0M sale-leaseback carrying $0.5M of annual rent cuts the senior loan from $12.0M to $10.5M at the same 3.0x cap, and coverage falls from 1.67x to 1.44x even after resizing the loan.
Sources
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review, calendar 2025 data from PitchBook and LevinPro HC
- Bain & Company, Global Healthcare Private Equity Report 2026 press release, 2025 estimates
- AMA Policy Research Perspective, Physician Practice Characteristics in 2024, published 2025
- AMA press release, 2024 Physician Practice Benchmark Survey
- FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks
- SRS Acquiom, 2026 M&A Earnout and Milestone Trends, 2025 deal data
- U.S. Small Business Administration, 7(a) loans program page, accessed November 2026